Desmopressin |
Catalog No.GC12303 |
A vasopressin receptor agonist
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 16679-58-6
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Desmopressin (dDAVP) is a synthetic peptide analog of natural pituitary hormone 8-arginine vasopressin (ADH) with hemostatic and anti-diuretic properties [1].
Desmopressin reduced the formation of lung nodules in F3II tumor cell injected BALB/c mice. In vitro, desmopressin blocked the F3II cell colony formation. Desmopressin could inhibit metastasis formation on V2 vasopressin receptors in both endothelial and cancer cells [1].
Desmopressin has been proved to increase the release of platelet adhesion promoting factors which is most likely von Willebrand factor (VWF), from endothelial cells (ECs). However, desmopressin had no direct effect on platelets [2].
The administration of desmopressin agglomerates in rats significantly reduced the urine production [3]. Apart from these, rats treated by desmopressin had demonstrated a stronger Pimonidazole staining in the outer and inner medulla compared to control. Desmopressin-treated rats revealed nuclear accumulation in the papilla, which was confirmed by HIF-1α immunostaining. Desmopressin-treated animals had shown a significant increase of HIF-target genes in the group of Desmopressin-regulated gene products including insulin-like growth factor binding proteins 1 and 3, fibronectin, hexokinase 2, angiopoietin 2, cathepsin D and cyclooxygenase 2. Desmopressin had been shown to cause the renal urine concentrating mechanism, leading to an upregulation of hypoxia-inducible gene expression and renal medullary hypoxia [4].
References:
1.Garona J1, Pifano M1, Scursoni AM2, Gomez DE1, Alonso DF3, Ripoll GV1.Insight into the effect of the vasopressin analog desmopressin on lung colonization by mammary carcinoma cells in BALB/c mice. Anticancer Res. 2014 Sep;34(9):4761-5.
2.Calmer S1, Ferkau A, Larmann J, Johanning K, Czaja E, Hagl C, Echtermeyer F, Goudeva L, Heuft HG, Theilmeier G. Desmopressin (DDAVP) improves recruitment of activated platelets to collagen but simultaneously increases platelet endothelial interactions in vitro. Platelets. 2014;25(1):8-15.
3.Balducci AG1, Ferraro L, Bortolotti F, Nastruzzi C, Colombo P, Sonvico F, Russo P, Colombo G. Antidiuretic effect of desmopressin chimera agglomerates by nasal administration in rats. Int J Pharm. 2013 Jan 20;440(2):154-60.
4.Dietrich A1, Mathia S, Kaminski H, Mutig K, Rosenberger C, Mrowka R, Bachmann S, Paliege A. Chronic activation of vasopressin V2 receptor signalling lowers renal medullary oxygen levels in rats. Acta Physiol (Oxf). 2013 Apr;207(4):721-31.
Cas No. | 16679-58-6 | SDF | |
Chemical Name | 1-(7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl)-N-(1-((2-amino-2-oxoethyl)amino)-5-((diaminomethylene)amino)-1-oxopentan-2-yl)pyrrolidine-2-ca | ||
Canonical SMILES | O=C(C1CSSCCC(NC(CC2=CC=C(O)C=C2)C(NC(CC3=CC=CC=C3)C(NC(CCC(N)=O)C(NC(CC(N)=O)C(N1)=O)=O)=O)=O)=O)N4C(C(NC(C(NCC(N)=O)=O)CCC/N=C(N)\N)=O)CCC4 | ||
Formula | C46H64N14O12S2 | M.Wt | 1069.22 |
Solubility | DMF: 1 mg/ml,DMSO: 5 mg/ml,PBS (pH 7.2): 2 mg/ml | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.9353 mL | 4.6763 mL | 9.3526 mL |
5 mM | 0.1871 mL | 0.9353 mL | 1.8705 mL |
10 mM | 0.0935 mL | 0.4676 mL | 0.9353 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *